Home › Compound Library › Memantine (Namenda)

Memantine (Namenda)

Nootropicprescriptionoral · inferred

Low-affinity, uncompetitive NMDA-receptor antagonist with voltage-dependent Mg2+-like block; approved for moderate-to-severe Alzheimer's disease. Titrated to 10 mg BID (IR) or 28 mg QD (XR). Plasma half-life ~60-80h. Oral bioavailability ~100%. Predominantly renally eliminated (~80% unchanged) with minimal CYP metabolism; urinary alkalinization markedly reduces clearance. Biohacker/harm-reduction use at low dose (5-10 mg) for post-acute withdrawal syndrome and opioid tolerance modulation is off-label and mostly based on animal data.

Projected serum levels — 10 mg, twice daily

Memantine (Namenda)
Memantine (Namenda) modeled serum levels, 10 mg twice daily over 23 days Population-based pharmacokinetic estimate. Steady state reached after approximately 9 days. 0 25 50 75 100 Day 0 Day 6 Day 11 Day 17 Day 23 Time on a regular schedule ≈ steady state · day 9
Memantine (Namenda) modeled serum levels with a loading dose of 30 mg, then 10 mg twice daily The first dose is larger so levels approach steady state faster. 0 25 50 75 100 Day 0 Day 6 Day 11 Day 17 Day 23 Time on a regular schedule

Maintenance schedule: 10 mg twice daily (oral).

Loading schedule: 30 mg on day 1, then 10 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~9 days: peak ≈ 84.4 mg, trough ≈ 77.6 mg body load. Population-based estimate over 23 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Nootropic
Route modeled
Oral
Model confidence
inferred
Half-life
2.9 days
Common dose
10 mg
Suggested maximum
28 mg/day
Reference dose range
5–28 mg (single dose)
Suggested cadence
twice daily
Validated against
20 mg oral — Cmax 0.028 mg/L at 5 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Memantine (Namenda) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Memantine (Namenda) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Memantine (Namenda) Serotonin risk

    25I-NBOMe and Memantine (Namenda) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Memantine (Namenda) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Memantine (Namenda) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Memantine (Namenda) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Memantine (Namenda) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Memantine (Namenda) Serotonin risk

    4-AcO-DMT (Psilacetin) and Memantine (Namenda) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + Memantine (Namenda) Serotonin risk

    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) and Memantine (Namenda) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 110 modeled interaction pairings for memantine (namenda) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex Kornhuber J et al. · Neuroscience Letters, 1995 DOI

    Seminal mechanistic study confirming memantine as a clinically relevant NMDA-receptor channel blocker at therapeutic concentrations.

  2. Memantine in moderate-to-severe Alzheimer's disease Reisberg B et al. · New England Journal of Medicine, 2003 DOI

    Pivotal phase 3 trial establishing memantine 10 mg BID efficacy on function and cognition in moderate-to-severe AD.

  3. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P · European journal of pharmacology, 1989 DOI

    This citation reports a primary research study involving Memantine (Namenda). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

3 published studies referenced in the app, each with a plain-language summary.